- Conditions
- Advance Solid Tumors, Advanced Malignant Solid Tumors
- Interventions
- a small molecular multi-target kinase inhibitor
- Drug
- Lead sponsor
- ThalassaX Therapeutics United States Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 135
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- treprostinil sodium
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • San Francisco, California • Torrance, California
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
- Interventions
- Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Kidney Failure, Chronic
- Interventions
- UKidney
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Liver Transplant
- Interventions
- treprostinil sodium, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
- Interventions
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Device
- Lead sponsor
- SPR Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Diego, California • Gainesville, Florida + 7 more
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- Qutenza (8% capsaicin)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pulmonary Arterial Hypertension, Right-Sided Heart Failure
- Interventions
- PET/MRI
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Torrance, California • Jacksonville, Florida
- Conditions
- Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
- Interventions
- Remodulin® (treprostinil sodium) Injection
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil, Non-Treprostinil PAH Medications
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
- Conditions
- Urinary Tract Infection Bacterial
- Interventions
- Bacteriophage Therapy
- Biological
- Lead sponsor
- Adaptive Phage Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Doral, Florida • Miami, Florida • Miami Gardens, Florida + 5 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR, Tyvaso Inhalation Solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Neuroblastoma
- Interventions
- Radiation: 131I-MIBG, Dinutuximab, Vorinostat
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Standardized meals
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- Right heart catheterization (RHC)
- Procedure
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Hartford, Connecticut • Lakeland, Florida + 38 more
- Conditions
- Healthy
- Interventions
- UT-15C, ethanol
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy Adult Participants
- Interventions
- ARN-75039 oral capsules, Placebo
- Drug
- Lead sponsor
- Arisan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Neuroblastoma
- Interventions
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin
- Biological · Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Up to 8 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
- Conditions
- Pulmonary Arterial Hypertension, Renal Dysfunction
- Interventions
- UT-15C SR (treprostinil diethanolamine)
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Orlando, Florida